Alnylam Is Now The Leader In The Clinical HBV RNAi Therapy Space

By: via Benzinga
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced the discontinuation of all its clinical RNAi programs, citing safety issues. ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.